KDM1A and prostate cancer: Molecular dockingsuggested that complex 4 occupies a substrate-competitivesite near Asp556, distinct from organic inhibitors like GSK2879552.In prostate cancer cells, complex 4 disrupted LSD1–H3K4me2binding, elevated H3K4me2 levels at the p21 and FOXA2 promoters, and suppressed GLUT1 expression.